Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.
ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.
The Vanguard Group reported a passive ownership stake in ASP Isotopes Inc common stock on a Schedule 13G. Vanguard beneficially owns 6,406,244 shares, representing 5.77% of the outstanding common stock. It has shared voting power over 873,110 shares and shared dispositive power over all 6,406,244 shares, with no sole voting or dispositive authority.
Vanguard states the shares are held in the ordinary course of business, not to change or influence control of ASP Isotopes. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies as before.
ASP Isotopes Inc. filed a current report to share that it issued a press release providing a production update on the Helium Project of Renergen Limited. The press release, dated January 29, 2026, is attached as Exhibit 99.1 and is incorporated by reference into the report.
The information is furnished under Regulation FD, meaning it is intended to ensure broad, non-selective disclosure. The company also notes that the press release contains forward-looking statements covered by the Private Securities Litigation Reform Act safe harbor provisions.
Encompass Capital Advisors LLCASP Isotopes Inc. common stock. The firm and its managing member, Todd J. Kantor, together report beneficial ownership of 6,413,362 shares, representing 5.13% of ASP Isotopes’ outstanding common stock as of the event date 01/16/2026.
Both Encompass and Kantor report shared voting and dispositive power over all 6,413,362 shares and no sole power to vote or dispose of any shares. They certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of ASP Isotopes, indicating a passive investment intent. A joint filing agreement confirms the Schedule 13G is filed on behalf of both reporting persons.
ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.
The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.
The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.
ASP Isotopes Inc. completed its previously announced acquisition of Renergen Limited on January 6, 2026. ASP Isotopes acquired all issued Renergen ordinary shares via a South African court-approved scheme of arrangement, paying with shares of its own common stock.
Renergen shareholders received 0.09196 ASP Isotopes common shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 new ASP Isotopes shares. Following the deal, Renergen became a direct, wholly owned subsidiary, and its shares will be delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes stock remains listed on Nasdaq and the JSE.
Renergen executives are joining ASP Isotopes’ leadership, with CEO Stefano Marani becoming President, Electronics and Space, and COO Nick Mitchell becoming Co-Chief Operating Officer. The consideration shares were issued in an unregistered transaction relying on Rule 802, and ASP Isotopes plans to file required acquired-business financial statements and pro forma information in a later amendment.
ASP Isotopes Inc. reports that the South African Takeover Regulation Panel has issued a compliance certificate for its planned acquisition of Renergen Limited. This clears a key regulatory step so the South African law scheme of arrangement can proceed to implementation. Under the Scheme, Renergen shareholders are to receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The company outlines a detailed timetable through early January 2026, including suspensions of Renergen trading on the JSE and ASX, the listing of ASP Isotopes consideration shares, the Scheme implementation date, settlement of new shares, and payment of cash for fractional entitlements. The disclosure also highlights cross-border settlement mechanics and reiterates risks that the Scheme may not be implemented as anticipated or that expected benefits from the Renergen acquisition may not be realized.
ASP Isotopes Inc. reported that, on December 17, 2025, it obtained all required regulatory approvals and clearances for its proposed offer to acquire all of the issued ordinary shares of Renergen Limited.
The transaction is structured as a scheme of arrangement under South African law, under which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date. The company also issued a press release describing the receipt of these approvals.
ASP Isotopes Inc. reported a leadership update. Founder and Executive Chairman Paul Mann will resume his role as the company’s Chief Executive Officer, while continuing as Executive Chairman, after a temporary leave of absence. His return to the dual role is effective January 19, 2026. The company disclosed this change in connection with a press release dated December 2, 2025.
ASP Isotopes Inc. (ASPI) is asking stockholders to vote at its virtual 2025 annual meeting on December 18, 2025. Investors are being asked to elect two Class III directors, Sipho N. Maseko and Todd Wider, M.D., to new three-year terms and to ratify EisnerAmper LLP as independent auditor for the year ending December 31, 2025. Only holders of common stock at the October 27, 2025 record date, when 110,840,122 shares were outstanding, may vote, with one vote per share.
The company highlights that six of seven directors are Nasdaq‑defined independent and describes an active audit, compensation, and nominating/governance committee structure. A new non‑employee director pay policy provides a $100,000 annual cash retainer plus equity awards. For 2024, Executive Chairman Paul Mann received total compensation of about $4.77 million, including salary, bonus, and restricted stock. Directors and executives together beneficially own 14.4% of outstanding shares.
FAQ
What is the current stock price of ASP Isotopes (ASPI)?
What is the market cap of ASP Isotopes (ASPI)?
